Ronald Asbury Andrews

This profile gathers the share dealings of Ronald Asbury Andrews across 4 companies, led by Insight Molecular Diagnostics Inc., Precipio, Inc. and Cerenome, Inc. In total, 24 filings cover trades dated from 26 July 2018 to 1 October 2026.

Purchases make up the whole of the open-market record (8 purchases, €331k). The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 11 share grants and 5 option exercises.

In size, the median ticket on the buying side is €46k. Of 6 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 5 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -28.5%. These figures describe past trades and do not predict future prices.

Most recently, on 1 October 2026, the filings show an option exercise in Cerenome, Inc. The last insider purchase was made public on 18 August 2022, 1,528 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.